To compare the VEGF levels in the aqueous humor of patients with Primary Open Angle Glaucoma (POAG) and non-glaucomatous eyes and reveal any potential statistically significant correlations.
Methods
We searched PubMed, from inception to December 31, 2021. Key search terms included VEGF and Glaucoma. All relevant studies that evaluated the VEGF levels in patients with POAG and in the control group were included in this systematic review. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis of Diagnostic Test Accuracy Studies (PRISMA-DTA) guidelines were followed. Data were extracted independently by 2 authors. Heterogeneity was statistically quantified by Q, H, and I2 statistics, and a meta-analysis was performed using the random-effects model.
Results
Seven cross-sectional studies were included in the meta-analysis. 144 eyes were enrolled in the POAG group and 162 eyes in the control group. The random effect model showed no statistically significant difference between the two groups (SMD =0.284, 95% CI = -0.173 to 0.741; P = 0.223), but we noticed a trend towards elevated VEGF levels in the aqueous humor of POAG patients. Significant heterogeneity was detected (I2 = 74.1%, P = 0.001).
Conclusions
This systematic review and meta-analysis indicates a trend towards elevated VEGF-A levels in the aqueous humor of patients with POAG and suggests a potential neuroprotective role of VEGF in patients with POAG. Future studies are required to evaluate the exact role of VEGF in POAG.
ThamY-CLiXWongTY, et al.Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology2014; 121: 2081–2090.
ColemanALMigliorS. Risk factors for glaucoma onset and progression. Surv Ophthalmol2008; 53: S3–10.
4.
BaudouinCKolkoMMelik-ParsadaniantzS, et al.Inflammation in Glaucoma: from the back to the front of the eye, and beyond. Prog Retin Eye Res2021; 83: 100916.
5.
Burgos-BlascoBVidal-VillegasBSaenz-FrancesF, et al.Tear and aqueous humour cytokine profile in primary open-angle glaucoma. Acta Ophthalmol (Copenh)2020; 98: e768–e772.
6.
SengerDRGalliSJDvorakAM, et al.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science1983; 219: 983–985.
KurokiMVoestEEAmanoS, et al.Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest1996; 98: 1667–1675.
9.
HouckKAFerraraNWinerJ, et al.The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol Baltim Md1991; 5: 1806–1814.
10.
FerraraNHenzelWJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun1989; 161: 851–858.
11.
ClaussMGerlachMGerlachH, et al.Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med1990; 172: 1535–1545.
12.
SuzukiMOzawaYKubotaS, et al.Neuroprotective response after photodynamic therapy: role of vascular endothelial growth factor. J Neuroinflammation2011; 8: 176.
13.
FordKMSaint-GeniezMWalsheT, et al.Expression and role of VEGF in the adult retinal pigment epithelium. Invest Ophthalmol Vis Sci2011; 52: 9478–9487.
14.
Saint-GeniezMMaharajASRWalsheTE, et al.Endogenous VEGF is required for visual function: evidence for a survival role on müller cells and photoreceptors. PloS One2008; 3: e3554.
15.
FrogerNMatontiFRoubeixC, et al.VEGF Is an autocrine/paracrine neuroprotective factor for injured retinal ganglion neurons. Sci Rep2020; 10: 12409.
16.
de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science1992; 255: 989–991.
17.
TermanBIDougher-VermazenMCarrionME, et al.Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun1992; 187: 1579–1586.
GilleHKowalskiJLiB, et al.Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. J Biol Chem2001; 276: 3222–3230.
20.
TakahashiTYamaguchiSChidaK, et al.A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells. EMBO J2001; 20: 2768–2778.
21.
ParkDYKimMChaSC. Cytokine and growth factor analysis in exfoliation syndrome and glaucoma. Invest Ophthalmol Vis Sci2021; 62: 6.
22.
PantalonAObadăOConstantinescuD, et al.Inflammatory model in patients with primary open angle glaucoma and diabetes. Int J Ophthalmol2019; 12: 795–801.
23.
KokubunTTsudaSKunikataH, et al.Characteristic profiles of inflammatory cytokines in the aqueous humor of glaucomatous eyes. Ocul Immunol Inflamm2018; 26: 1177–1188.
24.
KwonJ-WJeeD. Prostaglandin use is associated with increased vascular endothelial growth factor in the aqueous humor of glaucoma patients. Clin Experiment Ophthalmol2017; 45: 549–551.
25.
TakaiYTanitoMOhiraA. Multiplex cytokine analysis of aqueous humor in eyes with primary open-angle glaucoma, exfoliation glaucoma, and cataract. Invest Ophthalmol Vis Sci2012; 53: 241–247.
26.
HuD-NRitchRLiebmannJ, et al.Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. J Glaucoma2002; 11: 406–410.
27.
LeeJCChowNHWangST, et al.Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer Oxf Engl19902000; 36: 748–753.
28.
DimtsasGSGeorgiadiECKarakitsosP, et al.Prognostic significance of immunohistochemical expression of the angiogenic molecules vascular endothelial growth factor-A, vascular endothelial growth factor receptor-1 and vascular endothelial growth factor receptor-2 in patients with classical Hodgkin lymphoma. Leuk Lymphoma2014; 55: 558–564.
29.
CampochiaroPA. Molecular pathogenesis of retinal and choroidal vascular diseases. Prog Retin Eye Res2015; 49: 67–81.
30.
BednarzJWeichHARodokanaki-von SchrenckA, et al.Effect of differentiation on expression of genes for growth factors and growth factor receptors in human corneal endothelial cells. Ophthalmol Z Dtsch Ophthalmol Ges1996; 93: 268–274.
31.
KociokNHeppekausenHSchraermeyerU, et al.The mRNA expression of cytokines and their receptors in cultured iris pigment epithelial cells: a comparison with retinal pigment epithelial cells. Exp Eye Res1998; 67: 237–250.
32.
AielloLPNorthrupJMKeytBA, et al.Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol Chic Ill19601995; 113: 1538–1544.
33.
MurataTNakagawaKKhalilA, et al.The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. Lab Investig J Tech Methods Pathol1996; 74: 819–825.
34.
KvantaA. Expression and regulation of vascular endothelial growth factor in choroidal fibroblasts. Curr Eye Res1995; 14: 1015–1020.
35.
de Vries VictorABassilFLRamdas WishalD. The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep2020; 10: 13248.
36.
Reina-TorresEWenJCLiuKC, et al.VEGF As a paracrine regulator of conventional outflow facility. Invest Ophthalmol Vis Sci2017; 58: 1899–1908.
37.
SengerDRConnollyDTVan de WaterL, et al.Purification and NH2-terminal amino acid sequence of Guinea pig tumor-secreted vascular permeability factor. Cancer Res1990; 50: 1774–1778.
38.
SatchellSCBraetF. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol2009; 296: F947–F956.
39.
GavardJGutkindJS. VEGF Controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol2006; 8: 1223–1234.
40.
EsserSWolburgKWolburgH, et al.Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol1998; 140: 947–959.
41.
KizhatilKRyanMMarchantJK, et al.Schlemm’s canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process. PLoS Biol2014; 12: e1001912.
42.
PennJSMadanACaldwellRB, et al.Vascular endothelial growth factor in eye disease. Prog Retin Eye Res2008; 27: 331–371.
43.
PeachCJMignoneVWArrudaMA, et al.Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2. Int J Mol Sci2018; 19: E1264.
44.
CaoRXueYHedlundE-M, et al.VEGFR1-mediated Pericyte ablation links VEGF and PlGF to cancer-associated retinopathy. Proc Natl Acad Sci U S A2010; 107: 856–861.
45.
CouturierABousquetEZhaoM, et al.Anti-vascular endothelial growth factor acts on retinal microglia/macrophage activation in a rat model of ocular inflammation. Mol Vis2014; 20: 908–920.
46.
StittAWSimpsonDABoocockC, et al.Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours. J Pathol1998; 186: 306–312.
47.
LuoLUeharaHZhangX, et al.Photoreceptor avascular privilege is shielded by soluble VEGF receptor-1. eLife2013; 2: e00324.
48.
CarmelietPMoonsLLuttunA, et al.Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med2001; 7: 575–583.
49.
KendallRLThomasKA. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci U S A1993; 90: 10705–10709.
50.
AnisimovALeppänenV-MTvorogovD, et al.The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal2013; 6: ra52.
